Loading…
Sakar Healthcare (SAKAR)₹1,029+2.43%Pharmaceuticals
Sakar Healthcare is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 53.4 against a peer median of 53.4, and ROCE of 12.0% against a peer median of 12.0%, and latest-quarter sales growth of 49.9% against a peer median of 18.2%. By market cap it is #4 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikal | 2,772 | — | 4.0 | 2.9 | 0.57 | 0.3 | 1,714 | −49 | 6.0 | — | vs SAKAR |
| Dishman Carbogen Amcis | 2,616 | 162.2 | 3.0 | 1.6 | 0.46 | 0.0 | 2,927 | 97 | −4.3 | −352.0 | vs SAKAR |
| Fredun Pharmaceuticals | 2,507 | 55.0 | 21.1 | 15.7 | 0.80 | 0.0 | 637 | 33 | 89.9 | 85.7 | vs SAKAR |
| Sakar Healthcare | 2,284 | 53.4 | 12.0 | 10.0 | 0.13 | 0.0 | 251 | 30 | 49.9 | 119.8 | — |
| Sai Parenterals | 2,237 | 156.2 | 5.0 | 4.9 | 0.96 | 0.0 | 382 | 14 | 435.6 | 455.2 | vs SAKAR |
| Panacea Biotec | 2,206 | — | −2.0 | −2.4 | 0.03 | 0.0 | 641 | −7 | 19.5 | −44.3 | vs SAKAR |
| Beta Drugs | 2,089 | 39.0 | 19.0 | 18.9 | 0.11 | 0.0 | 384 | 41 | 33.0 | 58.3 | vs SAKAR |
| Indoco Remedies | 2,025 | 63.4 | 1.0 | −9.4 | 1.17 | 0.1 | 1,848 | −99 | 7.2 | — | vs SAKAR |
| Windlas Biotech | 2,007 | 30.8 | 16.0 | 12.2 | 0.06 | 0.6 | 906 | 66 | 18.2 | 0.0 | vs SAKAR |
| Venus Remedies | 1,941 | 15.9 | 21.0 | 15.7 | 0.02 | 0.7 | 769 | 103 | 13.3 | 30.0 | vs SAKAR |
| Syncom Formulations (India) | 1,885 | 21.6 | 27.1 | 20.2 | 0.00 | 0.5 | 488 | 76 | 7.7 | 56.3 | vs SAKAR |
| Peer median | 2,206 | 53.4 | 12.0 | 10.0 | 0.13 | 0.0 | 641 | 33 | 18.2 | 56.3 |
Listed companies closest to Sakar Healthcare in Pharmaceuticals include Hikal, Dishman Carbogen Amcis, Fredun Pharmaceuticals, Sai Parenterals, Panacea Biotec, Beta Drugs, Indoco Remedies, Windlas Biotech.
Hikal, with a market cap of ₹2,772 Cr.
Sakar Healthcare trades at a P/E of 53.4; the median of its peer set is 53.4. A P/E above or below the median is a description, not a judgement on value.
Sakar Healthcare's return on capital employed is 12.0%, above the peer median of 12.0%.